Literature DB >> 9511877

Nervous system Lyme disease.

J J Halperin1.   

Abstract

Lyme disease is a multisystem infectious disease caused by tick-borne spirochetes of the Borrelia burgdorferi group. The disease occurs primarily in specific areas of North America, Europe and Asia, reflecting the distribution of the hard-shelled Ixodes ticks that are required for disease transmission. Diagnosis of this infection can be somewhat problematic, although in clinically appropriate settings, serologic testing can be highly useful, particularly if Western blots are used to confirm borderline or positive results. The organism has several specific organotropisms-involvement of the heart, joints and nervous system being particularly common. The nervous system can be involved in one or more ways. Early in infection, patients tend to get a lymphocytic meningitis, cranial neuritis (particularly the facial nerves) or a painful radiculitis. Rarely, an encephalomyelitis can occur. In patients with more protracted and indolent involvement, a more disseminated mononeuropathy multiplex may occur, or a mild, non-focal alteration of cognitive function and memory, i.e. an encephalopathy. In patients with central nervous system involvement, the most sensitive diagnostic test is the demonstration of intrathecal production of anti-Borrelia burgdorferi antibody. Culture, polymerase chain reaction and other techniques appear to be less specific. In most instances, the disease is quite responsive to antimicrobial therapy. Oral treatment with doxycycline has been shown to be effective in meningitis. In more serious cases two to four week courses of parenteral ceffriaxone or cefotaxime are effective in the vast majority of patients.

Entities:  

Mesh:

Year:  1998        PMID: 9511877     DOI: 10.1016/s0022-510x(97)00290-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Neurology and the skin.

Authors:  O Hurko; T T Provost
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-04       Impact factor: 10.154

Review 2.  The differential diagnosis of multiple sclerosis.

Authors:  N Scolding
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

3.  Internuclear ophthalmoplegia as the first sign of neuroborreliosis.

Authors:  Willem J Hardon; Hans J J A Bernsen; Jose van Nouhuys-Leenders; Bert Mulder
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

Review 4.  [Cranial nerves - spectrum of inflammatory and tumorous changes].

Authors:  S F Nemec; G Kasprian; U Nemec; C Czerny
Journal:  Radiologe       Date:  2009-07       Impact factor: 0.635

Review 5.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

6.  Solution structure of decorin-binding protein A from Borrelia burgdorferi.

Authors:  Xu Wang
Journal:  Biochemistry       Date:  2012-10-08       Impact factor: 3.162

Review 7.  Lyme disease.

Authors:  Patricia K Coyle
Journal:  Curr Neurol Neurosci Rep       Date:  2002-11       Impact factor: 5.081

8.  The novel heparin-binding motif in decorin-binding protein A from strain B31 of Borrelia burgdorferi explains the higher binding affinity.

Authors:  Ashli Morgan; Xu Wang
Journal:  Biochemistry       Date:  2013-11-06       Impact factor: 3.162

Review 9.  Cognitive outcome in acute sporadic encephalitis.

Authors:  L Hokkanen; J Launes
Journal:  Neuropsychol Rev       Date:  2000-09       Impact factor: 6.940

10.  Adult-onset opsoclonus-myoclonus-ataxia syndrome as a manifestation of brazilian lyme disease-like syndrome: a case report and review of literature.

Authors:  Angelina Maria Martins Lino; Raphael Ribeiro Spera; Fernando Peixoto Ferraz de Campos; Christian Henrique de Andrade Freitas; Márcio Ricardo Taveira Garcia; Leonardo da Costa Lopes; Aleksander Snioka Prokopowitsch
Journal:  Autops Case Rep       Date:  2014-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.